 | This article needs additional citations for verification .(November 2017) |
| | This article needs additional citations for verification .(November 2017) |
The top 5 best selling pharmaceuticals 2015-2019. Sales in billion USD. [1]
| Rank | Drug | Main indication | Trade name | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| 1 | adalimumab | rheumatoid arthritis | Humira | 10.1 | 13.5 | 16.3 | 18.4 | 21.4 |
| 2 | apixaban | anticoagulant | Eliquis | 1.6 | 3.0 | 4.6 | 7.1 | 9.9 |
| 3 | etanercept | rheumatoid arthritis | Enbrel | 7.2 | 7.6 | 7.9 | 8.0 | 8.1 |
| 4 | ustekinumab | psoriasis | Stelara | 2.0 | 2.6 | 3.7 | 5.0 | 6.6 |
| 5 | pembrolizumab | oncology | Keytruda | 0.4 | 0.7 | 2.2 | 4.3 | 6.5 |
The top 16 best selling pharmaceuticals of 2017/18. [2]
| Rank | Drug | Main indication | Trade name | 2018 sales (million USD) | 2017 sales (million USD) |
|---|---|---|---|---|---|
| 1 | adalimumab | rheumatoid arthritis | Humira | 19 936 | 18427 |
| 3 | apixaban | anticoagulant | Eliquis | 9872 | 7395 |
| 4 | lenalidomide | multiple myeloma | Revlimid | 9685 | 8187 |
| 5 | nivolumab | oncology | Opdivo | 7570 | 5763 |
| 6 | pembrolizumab | oncology | Keytruda | 7171 | 3809 |
| 7 | etanercept | rheumatoid arthritis | Enbrel | 7126 | 7885 |
| 8 | trastuzumab | breast cancer | Herceptin | 6981 | 7013 |
| 9 | bevacizumab | colon cancer | Avastin | 6847 | 6686 |
| 10 | rituximab | non-Hodgkin's lymphoma | Rituxan, MabThera | 6750 | 7298 |
| 11 | rivaroxaban | anticoagulant | Xarelto | 6589 | 6234 |
| 12 | aflibercept | Eylea | 6551 | 5830 | |
| 13 | infliximab | Remicade | 5908 | 7152 | |
| 14 | Pneumococcal conjugate vaccine | Prevnar 13 Prevenar 13 | 5802 | 5601 | |
| 15 | ustekinumab | Stelara | 5156 | 4011 | |
| 16 | pregabalin | epilepsy | Lyrica | 4970 | 5065 |
Drugs with sales above $5 billion in 2015 included: [3] [4]
| Rank | Drug | Trade name | Type | Main indications | Company | Sales (USD millions/year) | ∆ vs 2014 |
|---|---|---|---|---|---|---|---|
| 1 | Adalimumab | Humira | Biologic | Rheumatoid arthritis | AbbVie Inc. | 14,012 | 1,469 |
| 2 | Ledipasvir/sofosbuvir | Harvoni | Small molecule | Hepatitis C | Gilead Sciences | 13,864 | 11,737 |
| 3 | Etanercept | Enbrel | Biologic | Rheumatoid arthritis | Amgen | 8,697 | 4,009 |
| 4 | Infliximab | Remicade | Biologic | Crohn's Disease Rheumatoid Arthritis | Johnson & Johnson | 8,355 | 1,487 |
| 5 | Rituximab | Mabthera Rituxan | Biologic | Lymphoma | Roche | 7,115 | 1,456 |
| 6 | Insulin glargine | Lantus | Biologic | Diabetes mellitus | Sanofi | 7,029 | 51 |
| 7 | Bevacizumab | Avastin | Biologic | Metastatic cancers | Roche | 6,751 | 270 |
| 8 | Trastuzumab | Herceptin | Biologic | Breast cancer | Roche | 6,603 | 265 |
| 9 | Lenalidomide | Revlimid | Small molecule | Multiple myeloma | Celgene | 5,801 | 821 |
| 10 | Sofosbuvir | Sovaldi | Small molecule | Hepatitis C | Gilead Sciences | 5,276 | (5,007) |
| 11 | Fluticasone propionate/salmeterol | Seretide Advair | Small molecule | Asthma | GlaxoSmithKline | 5,227 | (778) |
| 12 | Rosuvastatin | Crestor | Small molecule | Cardiovascular diseases | AstraZeneca | 5,017 | (495) |
For the fourth quarter of 2013, the largest selling drugs were: [5]
| Rank | Brand Name(s) | Generic Name | Sales Q1 2014 Sales ($000) | Change from Q4 2013 | Company(ies) | Disease/Medical Use | First Approval Date | Patent Expiration Date [6] [7] |
|---|---|---|---|---|---|---|---|---|
| 1 | Abilify | Aripiprazole | 1,602,329 | 2.23% | Generic | Psychosis, mania, and depression | Nov-2002 | 2014-Oct |
| 2 | Humira | Adalimumab | 1,561,861 | 3.86% | AbbVie | Crohn's disease; Rheumatoid arthritis | Dec-2002 | 2016-Dec |
| 3 | Nexium | Esomeprazole | 1,536,435 | 0.74% | Generic | Gastrointestinal disorders | Mar-2000 | 2014-May |
| 4 | Crestor | Rosuvastatin | 1,333,502 | 4.53% | AstraZeneca, Shionogi | Cholesterol | Nov-2002 | 2016-Jul |
| 5 | Enbrel | Etanercept | 1,189,844 | 1.46% | Amgen | Rheumatoid arthritis | Nov-1998 | 2012-Oct |
| 6 | Advair Diskus, Seretide | Fluticasone/salmeterol | 1,147,330 | 2.65% | GlaxoSmithKline | Asthma | Aug-2000 | 2012-Mar |
| 8 | Remicade | Infliximab | 994,020 | -2.71% | Centocor Ortho Biotech, Inc., Mitsubishi Tanabe Pharma | Crohn's disease; rheumatoid arthritis | Aug-1998 | n/a |
| 9 | Lantus Solostar | Insulin glargine | 939,691 | 9.39% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | 2011-Dec |
| 10 | Neulasta | Pegfilgrastim | 854,508 | -4.90% | Amgen | Neutropenia | Jan-2002 | Mon-20XX |
| 11 | Copaxone | Glatiramer | 851,351 | -4.69% | Generic | Multiple sclerosis | Dec-1996 | Nov-2014 |
| 12 | Rituxan, MabThera | Rituximab | 746,766 | -0.16% | Biogen Idec, Chugai Pharmaceutical, Genentech/Roche | Non-Hodgkin’s lymphoma; rheumatoid arthritis | Nov-1997 | Mon-20XX |
| 13 | Spiriva | Tiotropium bromide | 726,057 | 3.39% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Apr-2002 | 2018-Jul |
| 14 | Januvia | Sitagliptin | 700,941 | 3.63% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1996 | 2017-Nov |
| 15 | Lantus | Insulin glargine | 685,461 | 5.84% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | Dec-2011 |
| 16 | Atripla | Emtricitabine/tenofovir/efavirenz | 679,418 | 0.36% | Gilead Sciences, Inc. | HIV infection | Dec-1996 | Mar-2015 |
| 17 | Cymbalta | Duloxetine | 664,186 | -23.06% | Generic | Depression; anxiety disorders | Aug-2004 | Dec-2013 |
| 18 | Avastin | Bevacizumab | 650,208 | -1.25% | Genentech/Roche | Cancer | Feb-2004 | Mon-20XX |
| 19 | Lyrica | Pregabalin | 624,774 | 2.82% | Pfizer | Neuropathic pain | Jul-2004 | Jul-2019 |
| 20 | OxyContin | Oxycodone | 585,482 | -2.91% | Generic | Pain | Dec-1996 | Mon-20XX |
| 21 | Celebrex | Celecoxib | 580,332 | 5.23% | Generic | Osteoarthritis; rheumatoid arthritis | Dec-1998 | May-2014 |
| 22 | Epogen | Epoetin alfa | 503,493 | -2.08% | Amgen | Anemia | Jun-1989 | Mon-20XX |
| 23 | Truvada | Tenofovir/emtricitabine | 542,846 | 0.03% | Gilead Sciences | HIV infection | Aug-2004 | Mon-20XX |
| 24 | Diovan | Valsartan | 533,924 | -2.80% | Generic | Hypertension | Dec-1996 | Sep-2012 |
| 25 | Levemir | Insulin detemir | 424,186 | 9.34% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Dec-1990 | Mon-20XX |
| 26 | Gleevec, Glivec | Imatinib | 498,149 | 7.22% | Novartis | Leukemia | May-2001 | Jan-2015 |
| 27 | Herceptin | Trastuzumab | 473,632 | 1.53% | Chugai Pharmaceutical, Genentech/Roche | Breast cancer | Sep-1998 | Mon-20XX |
| 28 | Vyvanse | Lisdexamfetamine | 447,188 | 9.39% | Shire | Attention deficit hyperactivity disorder | Apr-2008 | Mon-20XX |
| 29 | Lucentis | Ranibizumab | 460,621 | -0.84% | Genentech | Macular degeneration | Dec-1990 | Mon-20XX |
| 30 | Zetia | Ezetimibe | 444,731 | 4.04% | Merck & Co., Schering-Plough | Cholesterol | Oct-2002 | 2017-Oct |
| 31 | Combivent | Ipratropium bromide/salbutamol | 391,404 | 20.28% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
| 32 | Symbicort | Budesonide/formoterol | 407,646 | 9.63% | AstraZeneca | Asthma | Aug-2000 | Mon-20XX |
| 33 | Namenda | Memantine | 434,766 | -6.00% | Generic | Alzheimer's disease | Oct-2003 | Apr-2014 [9] |
| 34 | NovoLog FlexPen | Insulin aspart | 364,870 | 7.84% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
| 35 | Xarelto | Rivaroxaban | 321,462 | 18.72% | Bayer | Oral anticoagulant | Dec-1996 | Sep-2012 |
| 36 | NovoLog | Insulin aspart | 344,235 | 3.86% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
| 37 | Humalog | Insulin lispro | 304,866 | 6.15% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
| 38 | Suboxone | Buprenorphine | 321,892 | -2.11% | Reckitt Benckiser Pharmaceuticals Inc. | Pain; opioid addiction | Aug-2000 | Mon-20XX |
| 40 | Viagra | Sildenafil | 300,463 | 3.26% | Pfizer | Erectile dysfunction | Mar-1998 | Mar-2012 |
| 41 | Seroquel XR | Quetiapine | 291,494 | 2.22% | Generic | Psychosis; depression | Sep-1997 | Mar-2012 |
| 33 | Incivo | Telaprevir | 370,899 | 0.00% | Johnson & Johnson | Hepatitis C[ citation needed ] | Dec-1990 | Mon-20XX |
| 35 | AndroGel | Testosterone gel | 351,737 | 5.47% | Generic | Low testosterone levels | Oct-2002 | Oct-2016 |
| 37 | Enoxaparin | Enoxaparin | 341,184 | 6.55% | Generic | Deep-vein thrombosis | Mar-1993 | 2012-Aug |
| 38 | Ritalin | Methylphenidate | 327,346 | 2.26% | Generic | Attention deficit hyperactivity disorder | Aug-2000 | Mon-20XX |
| 41 | ProAir HFA | Salbutamol | 306,461 | 10.87% | Teva Pharmaceuticals | Asthma; chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
| 43 | Alimta | Pemetrexed | 302,728 | 6.00% | Eli Lilly and Company | Cancer | Feb-2004 | Mon-20XX |
| 44 | Victoza | Liraglutide | 301,414 | 9.59% | Novo Nordisk | Diabetes mellitus type 2 | May-1909 | Mon-20XX |
| 47 | Synagis | Palivizumab | 289,704 | 0.00% | MedImmune | RSV infection | Feb-1998 | Aug-2012 |
| 48 | Avonex | Interferon beta 1a | 281,554 | -1.43% | Biogen Idec | Multiple sclerosis | May-1996 | Mon-20XX |
| 49 | Renvela | Sevelamer | 280,917 | 21.44% | Generic | Hyperphosphatemia | Apr-2002 | Apr-2016 [10] |
| 50 | Rebif | Interferon beta 1a | 280,548 | -6.27% | Serono | Multiple sclerosis | Feb-1998 | Mon-20XX |
| 51 | Cialis | Tadalafil | 280,518 | 4.58% | Eli Lilly and Company, Lilly Icos | Erectile dysfunction | Nov-2002 | 2017-Nov |
| 52 | Gilenya | fingolimod | 272,701 | 4.05% | Novartis Corporation | Multiple sclerosis | Feb-2000 | 2007-Jan |
| 53 | Nasonex | Mometasone | 272,345 | 5.67% | Schering-Plough | Allergic rhinitis | Oct-1997 | 2018-Oct |
| 54 | Stelara | Ustekinumab | 270,598 | 12.47% | Johnson & Johnson | Psoriasis; psoriatic arthritis | Apr-2000 | Mon-20XX |
| 55 | Restasis | Ciclosporin ophthalmic emulsion | 268,463 | 6.30% | Allergan, Inc, Lilly Icos | Dry eye syndrome | Nov-2002 | Mon-20XX |
| 56 | Budesonide | Budesonide | 268,201 | 26.81% | Generic | Asthma | Aug-2000 | Mon-20XX |
| 57 | Acetaminophen/hydrocodone | Acetaminophen/hydrocodone | 264,814 | 6.67% | Generic | Pain | Aug-2000 | Mon-20XX |
| 58 | Flovent HFA | Fluticasone propionate | 263,072 | 13.97% | GlaxoSmithKline | Asthma | Mar-1996 | Mon-20XX |
| 59 | Lovaza | Omega-3 fatty acid ethyl esters | 258,177 | 2.90% | GlaxoSmithKline | Cholesterol | Jun-2001 | Mon-20XX |
| 60 | Prezista | Darunavir | 251,372 | 3.54% | Johnson & Johnson | HIV infection | Jun-2006 | Mon-20XX |
| 61 | Isentress | Raltegravir | 248,924 | 0.72% | Merck & Co., Inc. | HIV Infection | Dec-1998 | Mon-20XX |
| 62 | Janumet | Sitagliptin/metformin | 247,150 | 4.65% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1998 | Mon-20XX |
| 63 | Procrit, Eprex | Epoetin alfa | 241,535 | -10.09% | Johnson & Johnson | Anemia | Dec-1990 | Mon-20XX |
| 64 | Doxycycline | Doxycycline | 241,381 | -5.65% | Generic | Bacterial infections | Dec-1996 | Nov-2011 |
| 65 | Orencia | Abatacept | 241,149 | 1.65% | Bristol-Myers Squibb Company | Rheumatoid arthritis | Aug-2000 | Mon-20XX |
| 66 | Amphetamine/dextroamphetamine | Amphetamine mixed salts | 240,482 | 2.78% | Generic | Attention deficit hyperactivity disorder; narcolepsy | Feb-2004 | Mon-20XX |
| 67 | Vesicare | Solifenacin | 240,435 | 5.37% | Astellas Pharma US | Overactive bladder | Feb-2000 | 2018-Nov |
| 68 | Dexilant | Dexlansoprazole | 238,897 | 7.57% | Takeda Pharmaceuticals North America, Inc | Gastrointestinal disorders | Dec-2004 | Jul-2012 |
| 69 | Humalog KwikPen | Insulin lispro | 238,418 | 11.02% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
| 70 | Neupogen | Filgrastim | 229,912 | -2.70% | Amgen | Neutropenia | Feb-1991 | Mon-20XX |
| 71 | Lidocaine | Lidocaine | 225,903 | 0.00% | Generic | Pain | Mar-1999 | Mon-20XX |
| 72 | Lunesta | Eszopiclone | 225,101 | 5.24% | Generic | Insomnia | Dec-2004 | April-2015 |
| 73 | Fenofibrate | Fenofibrate | 223,300 | -2.22% | Generic | Cholesterol | Feb-1998 | Mon-20XX |
| 74 | Zytiga | Abiraterone | 222,026 | 11.86% | Janssen Biotech, Inc. | Prostate Cancer | Dec-1998 | April-2015 |
| 75 | Reyataz | Atazanavir | 217,793 | -1.38% | Bristol-Myers Squibb | HIV infection | Jan-2003 | Mon-20XX |
| 76 | Sensipar | Cinacalcet | 216,657 | 13.71% | Amgen Inc. | Hyperparathyroidism | Apr-2000 | Mon-20XX |
| 77 | Metoprolol | Metoprolol | 215,111 | 2.99% | Generic | Hypertension | Jan-1992 | Mon-20XX |
| 78 | AcipHex | Rabeprazole | 214,251 | 10.03% | Janssen Pharmaceuticals, Inc, Johnson & Johnson | Gastrointestinal disorders | Aug-1999 | Nov-2013 |
| 79 | Synthroid | Levothyroxine | 213,424 | -2.50% | Generic | Hypothyroidism | May-1999 | Expired |
| 80 | Avonex Pen | Olmesartan | 211,917 | 13.59% | Biogen Idec, Forest Laboratories | Hypertension | Apr-2002 | Apr-2016 |
| 81 | Prevnar 13 | Pneumococcal conjugate vaccine | 209,367 | 6.41% | Pfizer | Pneumococcal disease | Feb-2000 | Jan-2007 |
| 82 | Xolair | Omalizumab | 207,891 | 1.91% | Genentech, Novartis | Asthma | 2003 | Mon-20XX |
| 83 | Lipitor | Atorvastatin | 207,542 | 4.23% | Generic | Cholesterol | Dec-1996 | Nov-2011 [12] |
| 84 | levothyroxine | Levothyroxine | 204,755 | 0.00% | Generic | Hypothyroidism | Aug-1990 | Mon-20XX |
| 85 | Benicar | Olmesartan/hydrochlorothiazide | 203,336 | 3.22% | Daiichi Sankyo | Hypertension | Jun-1909 | Mon-2016 |
| 86 | Stribild | Elvitegravir/cobicistat/emtricitabine/tenofovir | 202,642 | 0.00% | Gilead Sciences | HIV/AIDS | Apr-2000 | Mon-20XX [13] |
| 87 | Zostavax | Zostavax | 202,240 | 15.17% | Eisai, Merck & Co. | Herpes zoster | Aug-1999 | May-2013 |
| 88 | Pradaxa | Dabigatran | 200,697 | -0.53% | Boehringer Ingelheim, Lilly Icos | Oral anticoagulant | Oct-2010 | Mon-20XX |
| 89 | Vytorin | Ezetimibe/simvastatin | 199,625 | -3.02% | Merck & Co., Schering-Plough | Cholesterol | Jul-2004 | Mon-20XX |
| 90 | Tamiflu | Oseltamivir | 197,718 | 0.00% | Chugai Pharmaceutical, Hetero Drugs, Roche | Influenza | Oct-1999 | Mon-20XX |
| 91 | Xgeva | Denosumab | 197,711 | 3.24% | Amgen | Osteoporosis | Nov-2010 | Mon-20XX |
| 92 | Evista | Raloxifene | 196,929 | -4.31% | Eli Lilly and Company, Chugai Pharmaceutical | Osteoporosis | Dec-1997 | Jan-2013 |
| 93 | Xeloda | Capecitabine | 194,044 | 6.52% | Generic | Cancer | Jun-1909 | Mon-20XX [14] |
| 94 | Aranesp | Darbepoetin alfa | 185,225 | -9.22% | Amgen Inc. | Anemia | Jun-2001 | Mon-20XX |
| 95 | Ventolin HFA | Salbutamol | 183,060 | 0.00% | GlaxoSmithKline | Asthma; chronic obstructive pulmonary disease | May-1981 | Mon-20XX |
| 96 | divalproex sodium | Valproate | 181,554 | 0.00% | Generic | Epilepsy and bipolar disorder [15] | Jun-1909 | Mon-20XX |
| 97 | Afinitor | Everolimus | 180,719 | 0.03% | Novartis | Cancer | Jun-1909 | Mon-20XX |
| 98 | Betaseron, Betaferon | Interferon beta 1b | 179,216 | -3.72% | Bayer | Multiple sclerosis | Jul-1993 | Mon-20XX |
| 99 | Adderall XR | Amphetamine mixed salts | 177,505 | 3.31% | Generic | Attention deficit hyperactivity disorder | Oct-2001 | Mon-20XX |
| 100 | Complera | Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate | 174,933 | 0.00% | Gilead Sciences, Inc. | HIV | Jun-20XX | Mon-20XX |
Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in women. It can be taken orally, intravenously, or sublingually. Onset when taken orally is typically within twenty minutes and lasts for about two hours.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.
Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
The pharmaceutical industry discovers, develops, produces, and markets pharmaceutical drugs for the use as medications to be administered to patients, with the aim to cure and prevent diseases, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is administered by subcutaneous injection.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Pyrimethamine, sold under the brand name Daraprim among others, is a medication used with leucovorin to treat the parasitic diseases toxoplasmosis and cystoisosporiasis. It is also used with dapsone as a second-line option to prevent Pneumocystis jiroveci pneumonia in people with HIV/AIDS. It was previously used for malaria but is no longer recommended due to resistance. Pyrimethamine is taken by mouth.
Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.
Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.
Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.